ADINA BOROS: Open Payments
NPI 1194226928 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$615 in 19 payments from 9 companies in 2025. Trend: 2023 $481 · 2024 $712 · 2025 $615
Food & beverage: $503Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $175 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| Alkermes, Inc. | 3 | $75 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| ABBVIE INC. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $20 |
Products named: INGREZZA, FANAPT, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ARISTADA, COBENFY, VRAYLAR, LYBALVI.
Industry payments across AZ — which companies pay providers there.
